The role of urologist in the treatment of multiple sclerosis complication

Česká verzia

Authors: Gabriel Varga
Authors place of work: Lékařská fakulta MU Brno, Brno ; Urologická klinika FN Brno, Brno
Published in the journal: Ces Urol 2020; 24(3): 173-182
Category: Review article

Summary

Varga G. The role of urologist in the treatment of multiple sclerosis complication.

The review recapitulates the current treatment of urological problems associated with multiple sclerosis. The article is focused on the treatment of lower urinary tract dysfunction as the dominant symptomatology in this patient population. How‑ ever, it also marginally mentions treatment options for urinary tract infections and sexual dysfunction, which are often overlooked by the professional community

Keywords:

Multiple sclerosis – neurogenic dysfunction of the lower urinary tract – uroinfection – Sexual dysfunction

Zdroje

1. Havrdová E. Roztroušená skleróza. Praha: Maxdorf 2005; 11.

2. Landtblom AM, Fazio P, Fredrikson S, Granieri E. The first case history of multiple sclerosis: Augustus d´Este (1794–1848). Neurol Sci 2010; 31(1): 29–33.

3. Koldewijn EL, Hommes OR, Lemmens WA, et al. Relationship between lower urinary tract abnormalities and disease‑related parameters in multiple sclerosis. J Urol. 1995; 154(1): 169–173. 4. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999; 161(3): 743–757.

5. Zachoval R. Mikční dysfunkce u pacientů s roztroušenou sklerózou. In: Krhut J, editor. Neurourologie. Praha: Nakladatelství Galén 2005; 11: 77–83.

6. Khan F, Pallant JF, Shea TL, et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 2009; 31(19): 1567–1576.

7. de Seze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13(7): 915–928.

8. Wyndaele JJ, Kovindha A, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 4th Edition. Plymouth: Health Publication Ltd. 2009: 793–960.

9. Krhut J, Zapletalová O, Zachoval R, et al. Doporučení pro diagnostiku a léčbu symptomů dolních močových cest u pacientů s roztroušenou sklerózou v České republice – mezioborový mezioborový konsenzus expertů dle metodiky DELPHI. Cesk Slov Neurol N 2017; 80/-113(2): 233–237.

10. Blok B, Castro‑Diaz D, Del Popolo G, et al. Neuro‑urology. Arnhem, The Netherlands: EAU Guidelines Office; 2019.

11. McClurg D, Ashe RG, Marshall K, Lowe‑Strong AS. Comparison of pelvic floor muscle training, electro‑ myography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn. 2006; 25(4): 337–348.

12. Lucio AC, Campos RM, Perissinotto MC, et al. Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. Neurourol Urodyn 2010; 29(8): 1410–1413.

13. McClurg D, Ashe RG, Lowe‑Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis – a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 2008; 27(3): 231–237.

14. Fjorback MV, Van Rey FS, Rijkhoff NJM, et al. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn 2007; 26(4): 525–530.

15. Centonze D, Petta F, Versace V, et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler 2007; 13(2): 269–271.

16. Nasios G, Messinis L, Dardiotis E, Papathanasopoulos P. Repetitive Transcranial Magnetic Stimulation, Cognition, and Multiple Sclerosis: An Overview. Behav Neurol 2018; doi: 10.1155/2018/8584653.

17. De Ridder D, Ost D, Van der Aa F, et al. Conservative bladder management in advanced multiple sclerosis. Mult Scler 2005; 11(6): 694–699.

18. Krhut J, Borovicka V, Bilkova K et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity‑prospective, randomized, double‑blind, placebo‑controlled study. Neurourol Urodyn 2018; 37(7): 2226–2233.

19. Valiquette G, Herbert J, Maede‑D‚ Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double‑blind, crossover trial. Arch Neurol 1996; 53(12): 1270–1275.

20. Odeh M, Oliven A. Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis. J Clin Pharmacol 2001; 41(5): 582–584.

21. Abo Youssef N, Schneider MP, Mordasini L, et al. Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta‑analysis. BJU Int 2017; 119(4): 515–521.

22. Francomano D, Ilacqua A, Cortese A, et al. Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. J Endocrinol Invest 2017; 40(3): 275–279.

23. Schroder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a rando‑ mized, prospective, controlled multi‑center trial. Neurourol Urodyn 2016; 35(5): 582–588.

24. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998; 160(3 Pt 1): 892–896.

25. Cheng T, Shuang W‑b, Jia D‑d, et al. Efficacy and safety of onabotulinumtoxin A in patients with neurogenic detrusor overactivity: A systematic review and meta‑analysis of randomized controlled trials. PLOS ONE 2016; 11(7): e0159307.

26. De Ridder D, Van Poppel H, Baert L, et al. From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in Multiple Sclerosis using the PCI 5000 Bladdermanager(R). Spinal cord 1997; 35: 613–616.

27. Giannantoni A, Scivoletto G, Di Stasi SM, et al. Urological dysfunctions and upper urinary tract invol‑ vement in multiple sclerosis patients. Neurourol Urodyn 1998; 17(2): 89–98.

28. Wall BM, Dmochowski RR, Malecha M, et al. Inducible nitric oxide synthase in the bladder of spinal cord injured patients with a chronic indwelling urinary catheter. J Urol 2001; 165(5): 1457–1461.

29. Ozawa H, Uematsu K, Ohmori H, et al. Long‑term usefulness and safety of the contemporary balloon catheter. Nihon Hinyokika Gakkai Zasshi. 2005; 96(5): 541–547.

30. Chartier‑Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long‑term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000; 164(5): 1476–1480.

31. Zachoval R, Pitha J, Medova E, et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 2003; 70(1): 21–26.

32. Phé V, Pakzad M, Curtis C, et al. Urinary tract infections in multiple sclerosis. Mult Scler 2016; 22(7): 855–861.

33. Marrie RA, Elliott L, Marriott J, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014; 83(10): 929–937.

34. Mahadeva A, Tanasescu R, Gran B. Urinary tract infections in multiple sclerosis: under‑diagnosed and under‑treated? A clinical audit at a large University Hospital. Am J Clin Exp Immunol 2014; 3(1): 57–67.

35. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1(8441): 1313–1315.

36. Winkelmann A, Loebermann M, Reisinger EC, et al. Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol 2014; 175(3): 425–438.

37. Guo ZN, He SY, Zhang HL, et al. Multiple sclerosis and sexual dysfunction. Asian J Androl 2012; 14(4):530–535.

38. Shridharani AN, Brant WO. The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol 2016; 5(1): 88–101.

39. Foley FW, LaRocca NG, Sanders AS, Zemon V. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001; 7(6): 417–421.

40. Fragala E, Russo GI, Di Rosa A, et al. Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. Eur J Neurol 2015; 22(3): 485–492.

41. Lombardi G, Musco S, Wyndaele JJ, et al. Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study. Spinal Cord 2015; 53(12): 849–854.

42. Cardenas DD, Ditunno JF, Graziani V, et al. Two phase 3, multicenter, randomized, placebo‑controlled clinical trials of fampridine‑SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord 2014; 52(1): 70–76.

43. Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother 2009; 9(3): 341–350.